urapidil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
vasodilators	2796	34661-75-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: urapidil ebrantil eupressyl mediatensyl uraprene uropidil urapidil hydrochloride urapidil HCl	Molecular weight: 387.48 Formula: C20H29N5O3 CLOGP: 2.25 LIPINSKI: 0 HAC: 8 HDO: 1 TPSA: 68.36 ALOGS: -2.86 ROTB: 7

Molecule

Description

Molfile Inchi Smiles

Synonyms:

urapidil
ebrantil
eupressyl
mediatensyl
uraprene
uropidil
urapidil hydrochloride
urapidil HCl

Molecular weight: 387.48
Formula: C20H29N5O3
CLOGP: 2.25
LIPINSKI: 0
HAC: 8
HDO: 1
TPSA: 68.36
ALOGS: -2.86
ROTB: 7

Drug dosage:

Dose	Unit	Route
0.12	g	O
50	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	19 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	15 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	6.64 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	78 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.75 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.50 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1981	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	221.75	25.47	187	5650	263228	63219957
Hyponatraemia	143.00	25.47	102	5735	111798	63371387
Hyperkalaemia	139.23	25.47	77	5760	54126	63429059
Product prescribing error	98.05	25.47	48	5789	26241	63456944
Bradycardia	87.14	25.47	64	5773	73163	63410022
Mixed liver injury	64.78	25.47	22	5815	4713	63478472
Product monitoring error	61.85	25.47	21	5816	4495	63478690
Fall	58.51	25.47	118	5719	392216	63090969
Anaemia	58.46	25.47	100	5737	293330	63189855
Shock haemorrhagic	52.24	25.47	23	5814	9872	63473313
Pain	50.38	25.47	5	5832	740623	62742562
Hypotension	49.20	25.47	89	5748	272515	63210670
Patent ductus arteriosus	47.55	25.47	17	5820	4233	63478952
Ischaemic stroke	47.38	25.47	26	5811	17931	63465254
Haematoma	47.27	25.47	33	5804	34787	63448398
General physical health deterioration	45.91	25.47	73	5764	201329	63281856
Polyuria	45.57	25.47	20	5817	8522	63474663
Rhabdomyolysis	44.69	25.47	35	5802	43916	63439269
Diabetic metabolic decompensation	44.57	25.47	13	5824	1697	63481488
Labelled drug-drug interaction medication error	39.82	25.47	21	5816	13378	63469807
Renal impairment	38.57	25.47	44	5793	88311	63394874
Hyperlactacidaemia	38.04	25.47	13	5824	2836	63480349
Lactic acidosis	37.86	25.47	30	5807	38257	63444928
Walking disability	37.86	25.47	11	5826	1416	63481769
Acute generalised exanthematous pustulosis	37.61	25.47	19	5818	11080	63472105
Hypoglycaemia	37.09	25.47	36	5801	60029	63423156
Drug interaction	36.55	25.47	71	5766	229060	63254125
Resting tremor	34.09	25.47	9	5828	814	63482371
Pancreatic pseudoaneurysm	33.94	25.47	6	5831	78	63483107
Myoclonus	33.85	25.47	20	5817	15848	63467337
Premature baby	33.75	25.47	22	5815	20713	63462472
Bradyarrhythmia	33.60	25.47	11	5826	2104	63481081
Hypertensive crisis	31.91	25.47	19	5818	15267	63467918
Pyelonephritis	31.75	25.47	20	5817	17758	63465427
Haematoma muscle	31.21	25.47	9	5828	1128	63482057
Toxic encephalopathy	30.61	25.47	14	5823	6565	63476620
Haemorrhagic transformation stroke	30.48	25.47	9	5828	1226	63481959
Hepatocellular injury	30.44	25.47	23	5814	27358	63455827
Rash maculo-papular	29.42	25.47	24	5813	31872	63451313
Multiple organ dysfunction syndrome	27.75	25.47	30	5807	56722	63426463
Hypokalaemia	26.94	25.47	40	5797	103764	63379421
Left ventricular hypertrophy	26.91	25.47	12	5825	5303	63477882
Adenocarcinoma metastatic	26.12	25.47	5	5832	103	63483082
Metabolic acidosis	25.94	25.47	26	5811	45043	63438142
Hyperglycaemia	25.66	25.47	25	5812	41842	63441343
Agranulocytosis	25.50	25.47	20	5817	25114	63458071

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	139.15	21.56	208	5579	304780	34646364
Toxic epidermal necrolysis	118.63	21.56	62	5725	21584	34929560
Coma	67.95	21.56	58	5729	45620	34905524
Rash maculo-papular	61.42	21.56	45	5742	28406	34922738
Hepatic cytolysis	61.29	21.56	35	5752	14461	34936683
Ureteric compression	60.33	21.56	13	5774	267	34950877
Eosinophilia	55.52	21.56	41	5746	26181	34924963
General physical health deterioration	50.35	21.56	82	5705	128187	34822957
Drug reaction with eosinophilia and systemic symptoms	49.23	21.56	42	5745	32970	34918174
Hyperkalaemia	49.23	21.56	59	5728	69330	34881814
Haematoma muscle	43.98	21.56	14	5773	1354	34949790
Hyperthermia	43.27	21.56	25	5762	10552	34940592
Pyelocaliectasis	42.34	21.56	13	5774	1117	34950027
Hypoglycaemia	39.62	21.56	47	5740	54593	34896551
Fungal endocarditis	35.74	21.56	9	5778	371	34950773
Leukocytosis	34.61	21.56	30	5757	24035	34927109
Postrenal failure	34.13	21.56	9	5778	446	34950698
Histology abnormal	32.55	21.56	8	5779	298	34950846
Anaemia	32.17	21.56	98	5689	233237	34717907
Blood pressure ambulatory increased	31.86	21.56	6	5781	60	34951084
Cardiac autonomic neuropathy	31.60	21.56	6	5781	63	34951081
Shock haemorrhagic	31.59	21.56	21	5766	11333	34939811
Agranulocytosis	30.88	21.56	28	5759	23793	34927351
Chylothorax	29.32	21.56	9	5778	772	34950372
Disturbance in attention	28.84	21.56	28	5759	25917	34925227
Cerebral haemorrhage	28.59	21.56	32	5755	34905	34916239
Retinal disorder	27.34	21.56	9	5778	968	34950176
Haematuria	26.72	21.56	37	5750	50029	34901115
Supine hypertension	26.45	21.56	7	5780	352	34950792
Altered state of consciousness	25.99	21.56	25	5762	22868	34928276
Pancytopenia	25.97	21.56	52	5735	95105	34856039
Drug interaction	25.79	21.56	89	5698	225857	34725287
Haematochezia	25.75	21.56	35	5752	46499	34904645
Hypotension	25.02	21.56	87	5700	221562	34729582
Death	24.74	21.56	18	5769	398031	34553113
Proteinuria	24.33	21.56	22	5765	18620	34932524
Drug ineffective	23.17	21.56	25	5762	456726	34494418
Metabolic acidosis	22.88	21.56	32	5755	43648	34907496
Hypoglycaemic encephalopathy	22.84	21.56	6	5781	293	34950851
Vascular purpura	22.08	21.56	9	5778	1769	34949375
Encephalopathy	21.75	21.56	28	5759	35291	34915853
Septic shock	21.71	21.56	41	5746	71793	34879351

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	334.25	20.42	390	11057	519014	79213927
Hyperkalaemia	162.22	20.42	133	11314	114265	79618676
Hyponatraemia	112.56	20.42	133	11314	177715	79555226
Toxic epidermal necrolysis	106.44	20.42	71	11376	44510	79688431
Bradycardia	93.47	20.42	106	11341	135451	79597490
Product prescribing error	89.62	20.42	64	11383	44749	79688192
Rash maculo-papular	87.46	20.42	69	11378	56009	79676932
General physical health deterioration	86.16	20.42	147	11300	275091	79457850
Anaemia	85.01	20.42	193	11254	444822	79288119
Shock haemorrhagic	76.20	20.42	43	11404	20017	79712924
Hypoglycaemia	72.66	20.42	81	11366	101513	79631428
Haematoma muscle	72.05	20.42	23	11424	2592	79730349
Hepatic cytolysis	69.06	20.42	45	11402	27106	79705835
Hypotension	66.98	20.42	175	11272	440142	79292799
Fall	63.43	20.42	183	11264	487446	79245495
Ureteric compression	62.04	20.42	13	11434	270	79732671
Pain	61.71	20.42	13	11434	703789	79029152
Eosinophilia	60.59	20.42	51	11396	45294	79687647
Drug interaction	59.05	20.42	161	11286	415022	79317919
Drug reaction with eosinophilia and systemic symptoms	57.98	20.42	58	11389	64186	79668755
Coma	56.63	20.42	71	11376	100578	79632363
Pyelocaliectasis	55.92	20.42	15	11432	918	79732023
Agranulocytosis	54.78	20.42	48	11399	44982	79687959
Mixed liver injury	54.48	20.42	25	11422	7553	79725388
Labelled drug-drug interaction medication error	51.86	20.42	38	11409	27612	79705329
Hypertensive crisis	49.36	20.42	33	11414	20737	79712204
Disturbance in attention	46.08	20.42	46	11401	50755	79682186
Product monitoring error	44.77	20.42	23	11424	8883	79724058
Metabolic acidosis	44.48	20.42	57	11390	82472	79650469
Hyperthermia	43.68	20.42	29	11418	18008	79714933
Hepatocellular injury	41.16	20.42	42	11405	47551	79685390
Septic shock	40.20	20.42	67	11380	122734	79610207
Acute generalised exanthematous pustulosis	40.00	20.42	27	11420	17227	79715714
Pancytopenia	39.73	20.42	79	11368	165666	79567275
Encephalopathy	38.62	20.42	48	11399	67349	79665592
Lactic acidosis	38.55	20.42	49	11398	70310	79662631
Cerebral haemorrhage	37.84	20.42	44	11403	57629	79675312
Postrenal failure	36.44	20.42	10	11437	667	79732274
Rhabdomyolysis	36.09	20.42	58	11389	103073	79629868
Diabetic metabolic decompensation	33.76	20.42	14	11433	3318	79729623
Haemorrhagic transformation stroke	33.10	20.42	13	11434	2679	79730262
Fungal endocarditis	32.73	20.42	9	11438	605	79732336
Cardiac autonomic neuropathy	32.36	20.42	6	11441	64	79732877
Blood pressure ambulatory increased	32.36	20.42	6	11441	64	79732877
Resting tremor	32.34	20.42	11	11436	1510	79731431
Renal impairment	31.73	20.42	70	11377	157713	79575228
Pyelonephritis acute	31.56	20.42	16	11431	6007	79726934
Pancreatic pseudoaneurysm	31.27	20.42	6	11441	78	79732863
Leukopenia	30.93	20.42	58	11389	116455	79616486
Death	30.71	20.42	22	11425	566492	79166449
Myoclonus	30.69	20.42	28	11419	27632	79705309
Eczema	29.93	20.42	33	11414	40785	79692156
Inappropriate antidiuretic hormone secretion	29.91	20.42	27	11420	26286	79706655
Altered state of consciousness	29.69	20.42	34	11413	43788	79689153
Haematoma	29.62	20.42	37	11410	52158	79680783
Anuria	28.86	20.42	24	11423	20939	79712002
Proteinuria	28.68	20.42	29	11418	32473	79700468
Walking disability	28.66	20.42	11	11436	2132	79730809
Joint swelling	28.14	20.42	4	11443	288642	79444299
Cholestasis	28.08	20.42	36	11411	52073	79680868
Hypertriglyceridaemia	27.32	20.42	19	11428	12721	79720220
Haematuria	27.26	20.42	41	11406	68795	79664146
Polyuria	26.73	20.42	20	11427	14994	79717947
Thrombocytopenia	26.48	20.42	91	11356	265168	79467773
Ischaemic stroke	26.42	20.42	28	11419	33103	79699838
Supine hypertension	26.28	20.42	7	11440	417	79732524
Haematochezia	26.27	20.42	46	11401	87599	79645342
Nasopharyngitis	26.00	20.42	3	11444	253878	79479063
Subarachnoid haemorrhage	25.66	20.42	24	11423	24441	79708500
Product administration error	25.55	20.42	27	11420	31819	79701122
Hypernatriuria	25.17	20.42	4	11443	15	79732926
Leukocytosis	24.97	20.42	31	11416	43424	79689517
Pemphigoid	24.19	20.42	19	11428	15296	79717645
Hyperlactacidaemia	24.00	20.42	13	11434	5582	79727359
Peripheral swelling	23.52	20.42	5	11442	269612	79463329
Pyelonephritis	23.33	20.42	21	11426	20367	79712574
Acute pulmonary oedema	23.22	20.42	18	11429	14212	79718729
Completed suicide	22.61	20.42	4	11443	245763	79487178
Hypersensitivity	22.60	20.42	5	11442	262234	79470707
Headache	22.55	20.42	37	11410	653735	79079206
Posterior reversible encephalopathy syndrome	22.37	20.42	23	11424	26258	79706683
Bradyarrhythmia	21.69	20.42	11	11436	4135	79728806
Pallor	21.53	20.42	31	11416	50031	79682910
Adenocarcinoma metastatic	21.06	20.42	5	11442	186	79732755
Dermatitis exfoliative generalised	20.89	20.42	13	11434	7228	79725713
Alopecia	20.78	20.42	4	11443	231351	79501590
Victim of crime	20.77	20.42	6	11441	482	79732459
Fatigue	20.48	20.42	67	11380	929660	78803281

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C02CA06	CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING Alpha-adrenoreceptor antagonists
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D058668	Adrenergic alpha-1 Receptor Antagonists
MeSH PA	D000317	Adrenergic alpha-Antagonists
MeSH PA	D018674	Adrenergic Antagonists
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018490	Serotonin Agents
MeSH PA	D017366	Serotonin Receptor Agonists
MeSH PA	D014665	Vasodilator Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive emergency	indication	132721000119104

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	6.85	Basic
pKa2	2.48	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN	ANTAGONIST	Ki	8.85	WOMBAT-PK	KEGG DRUG
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN	ANTAGONIST	Ki	7.90	WOMBAT-PK	KEGG DRUG
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN	ANTAGONIST	Ki	7.10	WOMBAT-PK	KEGG DRUG
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	9.46	WOMBAT-PK

External reference:

ID	Source
D01333	KEGG_DRUG
C0077857	UMLSCUI
CHEBI:32278	CHEBI
CHEMBL279229	ChEMBL_ID
DB12661	DRUGBANK_ID
C015568	MESH_SUPPLEMENTAL_RECORD_UI
5639	PUBCHEM_CID
3169	INN_ID
64887-14-5	SECONDARY_CAS_RN
A78GF17HJS	UNII
39230	RXNORM
005866	NDDF
005867	NDDF
698807007	SNOMEDCT_US
734449004	SNOMEDCT_US
CHEMBL1256716	ChEMBL_ID

Pharmaceutical products:

None